TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

Samsung Bioepis has launched its Ontruzant rival to Herceptin in Brazil, claiming the first biosimilar trastuzumab to be supplied to the country’s public health system for early and metastatic HER2-overexpressing breast cancer.

Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.

Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.